Neurocrine Biosciences - NBIX Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NBIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBIX, but not buy additional shares or sell existing shares.
View NBIX analyst ratings or view top-rated stocks.

17 equities research analysts have issued 1 year price targets for Neurocrine Biosciences' stock. Their NBIX share price forecasts range from $76.00 to $154.00. On average, they expect the company's stock price to reach $113.38 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.

Neurocrine Biosciences' stock was trading at $85.17 at the beginning of 2022. Since then, NBIX shares have increased by 28.3% and is now trading at $109.24.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our NBIX earnings forecast.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its earnings results on Monday, November, 1st. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.28. The business earned $296 million during the quarter, compared to analysts' expectations of $297.02 million. Neurocrine Biosciences had a net margin of 0.94% and a trailing twelve-month return on equity of 0.88%. Neurocrine Biosciences's revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.62) earnings per share.

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Red Spruce Capital LLC (0.02%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBIX stock can currently be purchased for approximately $109.24.

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $10.45 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.11 on an earnings per share basis.

The company employs 900 workers across the globe.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.